Role of FIB-4 for reassessment of hepatic fibrosis burden in referral center

Roh, Yun Hwa; Kang, Bo Kyeong; Jun, Dae Won; Lee, Chul Min; Kim, Mimi

doi:10.1038/s41598-021-93038-6

Cited by 21 publications

(17 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In other words, a biomarker is an indicator of a particular pathological condition or some other physiological state of an organism. Many serological biomarkers have been used to diagnose and evaluate liver brosis, such as hyaluronic acid [34], CTGF [35], FIB-4 index [24], APRI score [25] and Forns index[36]. FIB-4 is a non-invasive, simple, rapid, and low-cost test that can assess the grade of liver brosis [37,38].…”

Section: Discussionmentioning

confidence: 99%

TET3 as a non-invasive screening tool for the detection of fibrosis in patients with chronic liver disease

Feng

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Ten-eleven translocation protein 3 (TET3) is one of the key enzymes in DNA demethylation which can be expressed in liver tissues. However, the clinical value of TET3 for diagnosis and treatment have not been reported previously. We investigated the diagnostic accuracy of serum TET3 as a non-invasive screening tool for liver fibrosis. Methods 212 patients with chronic liver disease from were enrolled in this study. Enzyme-linked immunosorbent assay was used to measure the serum levels of TET3. Receiver operating characteristics (ROC) were determined to examine the diagnostic accuracy of TET3 and combination model for diagnosis fibrosis. Results Serum TET3 level in fibrosis cases was significantly higher than that in non-fibrosis and controls, respectively. The areas under the ROC curve of the TET3 and fibrosis-4 index for liver fibrosis were 0.863 and 0.813, and 0.916 and 0.957 for liver cirrhosis. The combination of TET3 and fibrosis-4 index had a highly promising positive predictive value for detecting liver fibrosis and cirrhosis different stages of (93.5% and 100%) as compared with each diagnostic tool alone. Conclusion TET3 is related to the development of liver fibrosis and cirrhosis. The TET3-fibrosis-4 model enhances discriminatory power and represents a promising non-invasive tool for the diagnosis and screening of liver fibrosis.

show abstract

Section: Discussionmentioning

confidence: 99%

TET3 as a non-invasive screening tool for the detection of fibrosis in patients with chronic liver disease

Feng

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…[ 19 ] Therefore, calculation of the FIB‐4 in primary care may serve as a signal to pursue a diagnosis of chronic liver disease. [ 20 ] In addition, there is evidence that repeating measurements of FIB‐4 within a 5‐year period can, in comparison with a single measurement, help to identify individuals who are at higher risk of developing severe liver disease. [ 11 ] A Swedish epidemiological study found that an elevated FIB‐4 predicted the 10‐year risk of liver‐related events in the general population; however, 65% of those events occurred in participants with a low FIB‐4 index.…”

Section: Discussionmentioning

confidence: 99%

A higher FIB‐4 index is associated with an increased incidence of renal failure in the general population

et al. 2022

View full text Add to dashboard Cite

The Fibrosis‐4 index (FIB‐4) is a recommended noninvasive fibrosis test in patients at risk of liver fibrosis. Chronic liver diseases are often associated with kidney diseases. This study aimed to investigate the association between FIB‐4 and the development of renal failure among the general population. For this study, we used the Disease Analyzer database, which includes diagnoses and basic medical and demographic data of patients followed in general practices in Germany. Using these data, we extensively matched patients with a FIB‐4 index ≥ 1.3 (n = 66,084) to patients with a FIB‐4 index < 1.3 (n = 66,084). The primary outcome was the incidence of renal failure or chronic renal failure during a 10‐year period. Within 10 years of the index date, 9.2% of patients with a FIB‐4 < 1.3 and 10.6% of patients with a FIB‐4 ≥ 1.3 were diagnosed with renal failure (p = 0.007). The endpoint chronic renal failure was reached by 7.9% with a FIB‐4 < 1.3 and 9.5% with a FIB‐4 ≥ 1.3 (p < 0.001). A FIB‐4 index ≥ 1.3 was associated with a slight increase in renal failure incidence (hazard ratio [HR]: 1.08, p = 0.009). There was an increasing association between an increase in FIB‐4 index and the incidence of renal failure with the strongest association for a FIB‐4 index ≥ 2.67 (HR: 1.34, p = 0.001). In sensitivity analyses, a significant association was found for the age group of 51–60 years (HR: 1.38, p < 0.001), patients with arterial hypertension (HR: 1.15, p < 0.001), obese patients (HR: 1.25, p = 0.005), and patients with lipid metabolism disorders (HR:1.22, p < 0.001). Conclusion: A higher FIB‐4 index is associated with an increased incidence of renal failure. Therefore, the FIB‐4 index may be useful in identifying patients who are at risk not only for liver‐related events but also for renal disease.

show abstract

“…In other words, a biomarker is an indicator of a particular pathological condition or some other physiological state of an organism. Many serological biomarkers have been used to diagnose and evaluate liver brosis, such as hyaluronic acid [34], YKL-40, CTGF [35], FIB-4 index [24], APRI score [25] and Forns index[36]. FIB-4 is a non-invasive, simple, rapid, and low-cost test that can assess the grade of liver brosis [37,38].…”

Section: Discussionmentioning

confidence: 99%

“…This particular index combines AST, ALT, platelet count, and age and was originally used for staging liver brosis in patients with hepatitis C virus and HIV. More recently, this index has been used to quantify brosis grade in various liver diseases, including HCV or HBV infection, ALD, and NAFLD [24]. However, FIB-4 is susceptible to changes in ALT, AST, platelet count or patient age, thus resulting in lower accuracy when evaluating the degree of liver brosis [39].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

TET3 as non-invasive screening tool for the detection of fibrosis in patients with chronic liver disease

Feng

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

Ten-eleven translocation protein 3 (TET3) is one of the key enzymes in DNA demethylation which can be expressed in liver tissues. However, the clinical value of TET3 for diagnosis and treatment have not been reported previously. Here, we investigated whether TET3 can be detected by serological methods and evaluate the diagnostic accuracy of serum TET3 for non-fibrotic hepatitis, fibrotic hepatitis and cirrhosis. 212 patients with chronic liver disease (CLD) from were enrolled in this study. Clinical and biochemical data of all cases were obtained. Enzyme-linked immunosorbent assay was used to measure the serum levels of TET3. Receiver operating characteristics (ROC) were determined to examine the diagnostic accuracy of TET3 and combination model for diagnosis fibrosis. Univariable and multivariate analyses showed that levels of TET3 and FIB-4 index were independent predictors of liver fibrosis and cirrhosis. The areas under the ROC curve of the TET3 level and fibrosis-4 index for liver fibrosis were 0.863 and 0.813, and 0.916 and 0.957 for liver cirrhosis. When the TET3 level was associated with fibrosis-4 index, the AUROC was 0.943 for liver fibrosis and 0.990 for liver cirrhosis. The TET3-fibrosis-4 model showed a highly promising positive predictive value for detecting liver fibrosis and cirrhosis different stages of (93.50% and 100%, respectively) as compared with each diagnostic tool alone. TET3 is related to the development of liver fibrosis and cirrhosis. The TET3-fibrosis-4 model could enhance discriminatory power which could be represented a promising non-invasive tool for diagnosis and screening of liver fibrosis and cirrhosis.

show abstract

Role of FIB-4 for reassessment of hepatic fibrosis burden in referral center

Cited by 21 publications

References 22 publications

TET3 as a non-invasive screening tool for the detection of fibrosis in patients with chronic liver disease

TET3 as a non-invasive screening tool for the detection of fibrosis in patients with chronic liver disease

A higher FIB‐4 index is associated with an increased incidence of renal failure in the general population

TET3 as non-invasive screening tool for the detection of fibrosis in patients with chronic liver disease

Contact Info

Product

Resources

About